Brief: Unicycive Therapeutics Announces Enrollment of First Patient in Clinical Trial for Oxylanthanum Carbonate in Patients with Chronic Kidney Disease on Dialysis
18/12/2023 12:16
Dec 18 (Reuters) - Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST
PATIENT IN
PIVOTAL CLINICAL TRIAL FOR OXYLANTHANUM CARBONATE (OLC) IN
PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
Source text for Eikon: ID:nGNX1443tT
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss